NASDAQ:ACST • CA00430K8656
Past quarterly earnings results for ACASTI PHARMA INC (ACST), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.37 | -0.35 | -6.26% | -202.29% | - | - | ||
| Q4 2024 | -0.18 | -0.48 | 62.63% | 95.38% | - | - | ||
| Q3 2024 | -0.30 | -0.32 | 5.54% | 44.63% | - | - | ||
| Q2 2024 | -0.19 | -0.11 | -69.34% | -72.73% | - | - | ||
| Q1 2024 | -0.12 | - | -22.40% | - | - | |||
| Q4 2023 | -3.90 | -0.86 | -355.18% | -390.20% | - | - | ||
| Q3 2023 | -0.54 | -0.94 | 42.72% | 20.35% | - | - | ||
| Q2 2023 | -0.11 | - | - | - | - | |||
| Q1 2023 | -0.10 | - | - | - | - | |||
| Q4 2022 | -0.80 | - | - | - | -100.00% | |||
| Q3 2022 | -0.68 | -0.49 | -38.48% | - | - | -100.00% | ||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | - | - | 120K | - | - | |||
| Q3 2021 | - | - | 80K | - | - | |||
| Q2 2021 | -0.10 | -0.65 | 84.07% | 96.18% | - | - | ||
| Q1 2021 | -0.55 | -0.57 | 3.36% | 54.00% | - | - | ||
| Q4 2020 | 1.94 | -0.90 | 315.69% | - | - | - | ||
| Q3 2020 | -0.01 | - | - | - | - | |||
| Q2 2020 | -2.72 | -0.73 | -270.37% | - | - | - | ||
| Q1 2020 | -1.20 | -1.14 | -5.04% | - | - | - |
Notes
ACASTI PHARMA INC (ACST) last reported earnings on 8/9/2024.
ACASTI PHARMA INC (ACST) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ACASTI PHARMA INC (ACST) has beaten EPS estimates in 2 out of 4 releases.